YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AtriCure's fair value price target has shifted from about US$51.67 to about US$54.89, which reflects modest fine tuning in analyst models rather than a wholesale reset. Recent research ties these adjustments to how analysts balance new pro…
AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the busin…
AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day sh…
AXT Inc. (NASDAQ:AXTI) extended its winning streak to a fifth straight day on Monday, surging by as much as 16.4 percent in intraday trading to $81.50, as investors resumed buying positions amid its official membership in the S&P 600 index…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AtriCure (ATRC) been one of those stocks this year? A quick glance at the company's year-to-date per…
Investors in AtriCure, Inc. ATRC need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $25.00 Call had some of the highest implied volatility of all equity options today. Wh…
Have you been paying attention to shares of AtriCure (ATRC)? Shares have been on the move with the stock up 25.1% over the past month. The stock hit a new 52-week high of $55.72 in the previous session. AtriCure has gained 35.8% since the…
[investor adjusting financial portfolio using digital market data, concept of asset rebalancing, investment strategy, risk management and wealth preservation] primeimages/iStock via Getty Images S&P Dow Jones Indices on Friday said it will…
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to co…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AtriCure (ATRC) been one of those stocks this year? Let's take a closer look at the stock's year-to…
Company Logo Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursem…
MASON, Ohio, August 25, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain manageme…
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $134,470 Shares sold 3,…
Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $138,283 Shares sold 3,564 Post-…
Key Points Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company. All transacted shares…
Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings…
Investors in AtriCure, Inc. ATRC need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $50 Call had some of the highest implied volatility of all equity options today. What i…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AtriCure (ATRC) drew fresh investor attention after filing two shelf registrations related to employee stock ownership offer…
AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth pote…
Inspire Medical Systems Board appointment adds proven medical device leadership MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasi…
MASON, Ohio, July 27, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management…
This article first appeared on GuruFocus. Worldwide Revenue: $154 million, growth of 13% year over year. US Revenue: $125.6 million, increase of 13.6% year over year. Adjusted EBITDA: Over $27 million. Net Income: $9 million, compared to a…
Earnings Call Insights: AtriCure (ATRC) Q2 2026 MANAGEMENT VIEW * "AtriCure delivered solid second quarter results with worldwide revenue of $154 million and growth of 13%." (CEO, President & Director Michael H. Carrel) Carrel said U.S. gr…
AtriCure (ATRC) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.8%. EPS of $0.18 for the same period compares to -$0.02 a year ago. The reported revenue represents a surprise…
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This q…
Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million Second Quarter 2026 cash gene…
MASON, Ohio, July 02, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management…
AtriCure (ATRC) shares rallied 6.2% in the last trading session to close at $28.8. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.5% los…
Investors in AtriCure, Inc. ATRC need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $17.50 Call had some of the highest implied volatility of all equity options today. Wh…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. AtriCure (ATRC) has accelerated its BoxX-NoAF clinical trial by 12 months, with patient enrollment now targeted for com…
AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. (NASDAQ:ATRC) after the company delivered blowout Q1 2026 earnin…
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast. Continue Reading
MASON, Ohio, May 27, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management,…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Recent performance snapshot AtriCure (ATRC) has drawn investor attention after a difficult stretch…
Image source: The Motley Fool. DATE May 5, 2026, 4:30 p.m. ET CALL PARTICIPANTS President & Chief Executive Officer — Michael H. Carrel Chief Financial Officer — Angela L. Wirick Full Conference Call Transcript Michael H. Carrel: Great. Go…
Earnings Call Insights: AtriCure (ATRC) Q1 2026 MANAGEMENT VIEW * "AtriCure is off to a strong start in 2026 with worldwide revenue of $140 million in the first quarter, reflecting 14% growth year-over-year." (CEO, President & Director Mic…